Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 16/20 | 0.83 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.83 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.76 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.71 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833894 | 0.91 | KIT (1.00) | KITDYRK1AAAK1SLC2A1PIK3CA | |
| SCHEMBL12763510 | 0.86 | KIT (0.85) | KITDYRK1AAAK1SLC2A1PIK3CA | |
| SCHEMBL12763536 | 0.86 | DYRK1A (1.00) | KITDYRK1AAAK1SLC2A1PIK3CA | |
| SCHEMBL8387938 | 0.86 | AAK1 (1.00) | KITDYRK1AAAK1SLC2A1 | |
| SCHEMBL3765259 | 0.85 | SLC2A1 (1.00) | KITDYRK1AAAK1SLC2A1PIK3CA | |
| SCHEMBL1516600 | 0.85 | KIT (0.83) | KITDYRK1AAAK1SLC2A1PIK3CA | |
| SCHEMBL17211640 | 0.85 | KIT (0.88) | KITDYRK1AAAK1SLC2A1PIK3CA | |
| SCHEMBL17200869 | 0.85 | KIT (0.91) | KITDYRK1AAAK1SLC2A1PIK3CA | |
| SCHEMBL15555511 | 0.85 | KIT (0.83) | KITDYRK1AAAK1SLC2A1PIK3CA | |
| SCHEMBL15554740 | 0.85 | KIT (0.91) | KITDYRK1AAAK1SLC2A1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014004863-A2 | COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| EP-2295433-A2 | JNK inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | KIT 3148/4885DYRK1A 1619/4885AAK1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.